Open AccessIdentification of the domains of the fibronectin‐binding protein I of Streptococcus pyogenes responsible for adjuvanticity
Author(s) -
Schulze Kai,
Guzmán Carlos A.
Publication year - 2003
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00071-3
Subject(s) - adjuvant , streptococcus pyogenes , antigen , isotype , immune system , biology , nasal administration , microbiology and biotechnology , immunogenicity , antibody , fibronectin , immunoglobulin g , recombinant dna , immunology , biochemistry , bacteria , monoclonal antibody , cell , staphylococcus aureus , genetics , gene
Intranasal administration of antigens coupled to full‐length fibronectin‐binding protein I (SfbI) of Streptococcus pyogenes results in the elicitation of improved humoral and cellular immune responses, at both systemic and mucosal levels. We want to evaluate if SfbI also exhibits adjuvant properties when co‐administered with the antigen, as well as identify the minimal domain responsible for its adjuvanticity. To achieve this aim, mice were immunized by the intranasal route with the model antigen β‐galactosidase (β‐gal) co‐administered with recombinant proteins spanning different portions of the SfbI protein. The obtained results demonstrated that the adjuvant properties of SfbI were maintained intact when admixed to the model antigen. Similar kinetics and absolute titers of β‐gal‐specific IgG antibodies as well as a dominant IgG 1 isotype response pattern were observed using SfbI derivatives spanning either the aromatic and proline‐rich (H10) or the fibronectin‐binding (H12) domains, respectively. The use of all tested derivatives also stimulated the elicitation of efficient β‐gal‐specific IgA responses in lung lavages (23–25% of the total IgA). The obtained results suggest that different sub‐domains of the SfbI protein can be used as adjuvants for the development of mucosal vaccines.